REGN7544

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals

Conditions

Healthy VolunteersPostural Orthostatic Tachycardia Syndrome (POTS)Sepsis-Induced Hypotension

Phase 1

A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants

CompletedNCT05970718

Regeneron PharmaceuticalsHealthy Volunteers

Start: 2023-08-07End: 2024-07-22Updated: 2024-08-12

Phase 2

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

CompletedNCT06593600

Regeneron PharmaceuticalsPostural Orthostatic Tachycardia Syndrome (POTS)

Start: 2024-11-13End: 2026-07-08Updated: 2026-07-21

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

CompletedNCT06608901

Regeneron PharmaceuticalsSepsis-Induced Hypotension

Start: 2025-05-05End: 2026-04-28Updated: 2026-05-20

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients with Sepsis-Induced Hypotension

RecruitingCTIS2024-514946-35-00

Regeneron Pharmaceuticals Inc.Sepsis-Induced Hypotension

Start: 2025-06-24Target: 31Updated: 2025-10-24

Related Papers

Abstract 4359840: A First-In-Human Phase 1 Study of the Safety, Tolerability, and Pharmacodynamics of REGN7544, a Novel Natriuretic Peptide Receptor 1–Blocking Monoclonal Antibody

Circulation2025-11-03